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Abstract A 38-year-old male and a 36-year-old female
experienced red-brown urine discolouration after 2 and
3 days, respectively, during the use of mesalamine for
inflammatory bowel disease. Both patients mentioned that
the urine discoloured after contact with sodium hypochlo-
rite detergent in toilet water. Mesalamine and the inactive
metabolite N-acetyl-5-aminosalicylic acid are primarily
excreted in the urine. We hypothesised a possible reaction
with sodium hypochlorite and/or light. Naranjo assessment
scores of 9 and 6 were obtained for the reports, indicating a
certain and probable relationship, respectively, between the
red-brown urine discolouration and the use of the suspect
drug mesalamine. Knowledge of this harmless reaction is
desirable to avoid unnecessary physical examination and
worry.
Key Points
The use of sodium hypochlorite as toilet detergent is
related to a red-brown urine discolouration in
patients taking mesalamine.
It seems that the red-brown discolouration relates to
a harmless reaction.
Polymerisation of mesalamine and/or metabolites
could be a theoretical mechanism of this
discolouration.
Introduction
Mesalamine is indicated for the treatment of ulcerative
colitis and Crohn’s disease [1]. The exact working mech-
anism of mesalamine is not fully understood, but it appears
to have anti-inflammatory properties. The drug blocks
interleukin-1 and tumour necrosis factor-a. Mesalamine
also inhibits the cyclo-oxygenase pathway, leading to
inhibition of prostaglandin E2 in inflamed intestine.
Blocking of the lipoxygenase pathway also inhibits the
production of leukotrienes [2]. The most common adverse
drug reactions (ADRs), as described in the Summary of
Product Characteristics (SmPC), are headache, rash and
gastrointestinal symptoms, including diarrhoea, nausea,
vomiting and abdominal pain [1]. Mesalamine is also
associated with the renal ADRs of renal failure, interstitial
nephritis and haematuria [1, 3]. In the period from August
2009 to April 2015, the Netherlands Pharmacovigilance
Centre Lareb received two case reports of red-brown urine
discolouration in association with mesalamine [4]. Both
cases were reported by patients and the urine discoloured
after contact with the toilet bowl. This discolouration could
worry patients and/or encourage healthcare professionals to
undertake further examination. This article describes these
two reports and summarises the available literature.
Case Reports
Patient A (Report Date April 2015)
This case concerned a 38-year-old male with a history of
Crohn’s disease. The patient reported separate several
episodes of a red-brown deposit in the toilet bowl after the
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start of mesalamine in 1999 (Pentasa slow-release
500 mg tablet). The latest episode occurred in April 2015,
2 days after the use of mesalamine. The patient had a mild
form of Crohn’s disease that had been stable for 6–8 years
and only used mesalamine during episodes of exacerba-
tions. Due to an exacerbation in September 2014, the daily
dose of mesalamine was increased from 2 to 4 g. During
this dose escalation, the patient recognised the same red-
brown deposit that had occurred during previous use. In
January 2015, the mesalamine was tapered over a period of
2 months to 2 g once daily and he remained stable. The
patient continued 2 g once daily for his report to Lareb.
Concomitant medications being taken were simvastatin and
unspecified multivitamins. The patient stated that he
experienced no physical complaints. He observed that the
urine initially had a normal colour and developed the red-
brown colour after contact with the water in the toilet bowl.
Most of the time the persistent deposit did not appear
directly after contact with the toilet water but developed
after a few days, despite flushing the toilet. Of note, the
deposit in the toilet bowl was more intense during the use
of an increased dose of 4 g a day. The patient is under the
care of a gastroenterologist and has normal renal function.
The patient wondered whether the use of detergents could
have caused this kind of discolouration and therefore he
cleaned his toilet in the morning with a chlorine-containing
detergent. In the evening a red-brown deposit had devel-
oped in the toilet bowl and on the seat and the water was
unaffected. As the patient wanted more information on the
possibility of the discolouration being the result of a
reaction with the sodium hypochlorite detergent, he
reported it to Lareb.
After the report had been assessed, the Pharmacovigi-
lance Centre Lareb asked the patient to collect his urine
and to add household bleach as a test, to which he agreed
(Fig. 1). The urine (40 mL) was mixed with 20 mL of
sodium hypochlorite bleach and within a few minutes the
discolouration developed. After shaking the mixture, all of
the urine showed a red-brown discolouration.
Patient B (Report Date August 2009)
This case concerned a 36-year-old woman with ulcerative
colitis, for which she is treated with 2 g of mesalamine
(Pentasa sachet 2 g prolonged-release granules) twice
daily. She experienced occasional mild exacerbations with
diarrhoea and abdominal pain. Since she started taking
mesalamine in June 2009, her urine appeared red-brown in
the toilet bowl, but only when she had recently cleaned the
toilet with sodium hypochlorite detergent. Interestingly, the
discolouration did not appear when detergents without
sodium chlorite were used. When the patient added a drop
of sodium hypochlorite detergent to her normal-coloured
urine in the toilet, the same red-brown discolouration
occurred immediately. The patient was taking no other
concomitant therapy. The patient regularly sees her gas-
troenterologist, who recognised this phenomenon from
other patients. The patient is still taking mesalamine and
the phenomenon is still present when cleaning the toilet.
Discussion
Urine discolouration can be caused by several drugs, food
intake and diseases. Haematuria is likely the most common
cause of red urine. Likewise, the disordered haem pro-
duction in patients with porphyria can result in red-brown
discolouration [5]. Rhabdomyolysis can also result in red
discolouration due to myoglubinuria [6]. A red-brown
urine discolouration could be perceived as a sign of pos-
sible renal impairment or other diseases; however, neither
of the described patients are known to have an impaired
renal function or physical abnormalities. Furthermore,
various drugs are associated with red and/or brown dis-
colouration, e.g. rifampicin, doxorubicin, metronidazole,
methyldopa, levodopa and sulfasalazine. A notable differ-
ence from the described mesalamine cases is that the urine
of patients taking the above-mentioned drugs, such as
sulfasalazine, is already discoloured at micturition.
A PubMed search was conducted and it was found that
two cases of red-brown urine associated with mesalamine
have been reported previously by Sacks and Davis [7].
Both of the male adolescents in these reports experienced
the same red-brown urine discolouration after contact with
sodium hypochlorite bleach. A similar experiment was
performed to that performed by Patient A, and after adding
sodium hypochlorite bleach to the collected urine the dis-
colouration developed spontaneously. To our knowledge,
there are no other published reports of this association after
a chemical reaction with drugs structurally related to
mesalamine (sulfasalazine, olsalazine and 4-aminosalicylic
acid). Notably, there has been discussion regarding this
phenomenon in several patient forums and blogs [8].
Case reports from Altmann and Mansell [9] do, how-
ever, describe urine discolouration in patients using
methyldopa or levodopa after contact with lavatory bleach
and exposure to light. Normal biotransformation of
methyldopa produces a variety of metabolites [10]; pre-
sumably, these metabolites have properties that form
melanin by spontaneous polymerisation, which results in
darkening of the urine. Melanins are polymers of phenolic
compounds (e.g. dopaquinone, benzothiazole) that are
formed by an extensive bio pathway. Melanin is an
aggregate of smaller component molecules such as
pheomelanin and eumelanin; both of these are initially
formed by oxidation of tyrosine and then undergo
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cysteinylation and cyclisation, respectively. The end pro-
duct is ultimately formed by polymerisation of several
different derivatives [11]. The formation of melanin by
polymerisation requires a urine pH of 7 or more [9]. Alt-
mann and Mansell [9] found that urine samples that were
made alkaline in patients treated with methyldopa or
levodopa turned black on exposure to sunlight.
Mesalamine is acetylated by the enzyme N-acetyltrans-
ferase 1 (NAT1) in the liver and gut mucosal wall into the
metabolite N-acetyl-5-aminosalicylic acid (N-Ac-5ASA).
Evidence from the literature indicates that NAT1 is poly-
morphic, but that these polymorphisms are associated with
relatively minor effects on acetylation function [12]. It is
unknown whether the patients in our reports have a NAT1
polymorphism, but if so we would expect no significant
effect on the propensity of discolouring. Furthermore, this
acetylation is minimal when mesalamine and N-Ac-5ASA
are both secreted back into the lumen by the drug efflux
pump P-glycoprotein, excreted in the faeces, absorbed via
the colon into the blood and, lastly, eliminated in the urine
[13]. The theory is that N-Ac-5ASA and/or mesalamine
react with the sodium hypochlorite-containing bleach.
Sodium hypochlorite usually has a pH of 11–13 and could
therefore initiate the reaction as described by Altmann and
Mansell [9]. According to the cases reported by Altmann
and Mansell [9], it is also possible that a similar poly-
merisation of mesalamine and/or N-Ac-5ASA could cause
the discolouration of the urine. Perhaps due to the alkaline
environment, partial deprotonation of N-Ac-5ASA and
mesalamine could also contribute to this reaction.
The two reports received by Lareb emphasise the value
of consumer reporting. Since the introduction of the
national spontaneous reporting system in 2003 to the
general public, consumers have now become the largest
group of reporters in the Netherlands [14]. The quality of
consumer reports are generally good and these reports
highlight via first-hand information the real-life experi-
ence of an ADR. Consumers also report different ADRs
than healthcare professionals [14, 15]. Being uncon-
strained with regards to the probability of causality,
consumers may report relevant ADRs that healthcare
professionals may not recognise initially or consider to be
unlikely. Patient B’s gastroenterologist recognised the
phenomenon, but it is conceivable that not every gas-
troenterologist will establish a direct relationship between
urine discolouration, mesalamine therapy and the use of a
specific detergent. The two reports received provide
important information about a harmless reaction as this
phenomenon probably concerns a lot of other patients
using mesalamine.
Conclusion
Based on the described reports and the case reports in the
literature, we suggest a causal relationship between red–
brown discolouration of urine after contact with sodium
hypochlorite detergent and the use of mesalamine. The
Naranjo assessment scores for cases A and B were 9 and 6,
indicating a certain and probable relationship, respectively.
This seems to be a harmless reaction as the patients
experienced no physical complaints and in both the Lareb
cases and those described by Sacks and Davis [7], the
patients were under the care of a gastroenterologist. In the
differential diagnosis it is important to be aware that the
use of sodium hypochlorite as a toilet detergent could be
the cause of coloured deposits in and on the toilet bowl.
The presence of sodium hypochlorite does not exclude the
possibility of renal impairment; therefore, it is important to
distinguish already discoloured urine from normal-
coloured urine that only discoloured after contacting the
toilet bowl. Knowledge of this harmless reaction is desir-
able to avoid unnecessary physical examination and worry.
Thus, to inform and reassure patients, it might be helpful to




sodium hypochlorite bleach to
normal-appearing urine (left,
right). Agitation discoloured the
urine completely (right)
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